Health Care Professionals
For further information on Aglucator® prebiotics please do not hesitate to contact us at info@ozstartherapeutics.com
Product Innovation
Agulcator® is synergistic with sulphonylurea-class drugs, a derivative of sulfonamide antibiotics.
Aglucator® significantly counteracts the microbiome dysbiosis linked with sulphonylurea use.
Agulcator® promotes the growth of beneficial gut bacteria and reduces the population density of detrimental gut microbes.
However, Aglucator® has more than just a prebiotic effect. While intake of sulphonylurea reduces blood glucose, adjunctive intake of Aglucator® helps to stabilise some aspects of diabetes. Aglucator® not only improves the effectiveness and the duration of glycaemic control by sulphonylureas but its adjunctive intake results in improved pancreatic function. To learn more about the mechanism of action please click below and refer to our EASD conference presentation, our published clinical trial paper, and a review article placing this novel concept into perspective.
Problem with currently available anti-diabetes treatments
The currently marketed anti-diabetes drugs can have significant side effects and limited efficacy. This latter problem equates to the progressive nature of the disease and commonly requires the use of multiple drugs in combination to adequately control glycaemia. This is costly and may further increase the risk of side effects. Diabetes treatment is, therefore, often inadequate and poses major challenges. This may include progression to insulin which many patients find unpalatable through the need to self-inject, concerns about side effects (specifically weight gain and hypoglycaemia), and ever-increasing costs of diabetes management.
In countries where the majority of people with T2D live, diagnosed patients are often initially prescribed sulphonylurea and these agents have been in wide use for over 50 years. However, many patients taking sulphonylurea experience side effects including increased risk of hypoglycemia and weight gain, and reduced efficacy often seen within 12 months. We hypothesized that these side effects and loss of effectiveness are due to previously little-recognized ANTIBIOTIC properties of these agents. Sulphonylureas are derivatives of sulphonamide antibiotics (Sulpha drugs) and these outlined problems may be the result of their chronic intake leading to an inadvertent reduction in essential gut-beneficial bacteria and an increase in detrimental bacteria.
Solution provided
We have shown in a peer-reviewed published clinical study that adjunctive intake of our patented prebiotic OZ101 (a tableted form of Aglucator®) in combination with the sulphonylurea class of anti-diabetes drugs will help restore essential beneficial gut bacteria in people with type 2 diabetes. We have also found evidence that this combination is associated with improvements in glucose control with reduced risk of side effects. Our experience through a range of clinical case studies suggests that this combination can sustain near-normal blood glucose levels for several years without the need for a sulphonylurea dose increase or intake of other anti-diabetes medications.
About prebiotic Agulcator®
OZ101 tablets are composed of plant-derived water-extracted natural carbohydrate that has been given “Generally Recognised As Safe (GRAS)” status by the USFDA, and equivalent by TGA, EMEA, and other major regulatory authorities. OZ101 will be marketed as a “food for special medical purpose” and must be used under a physician’s supervision.
Food for special medical purposes means a food that is specially formulated for the dietary management of individuals whose capacity is limited or impaired to take, digest, absorb, metabolize, or excrete ordinary food or certain nutrients in ordinary food; and whose dietary management cannot be completely achieved without the use of the food. It is used under medical supervision; and for the dietary management of a disease, disorder, or medical condition. A food for special medical purposes must not be sold to a consumer, other than from or by (a) a medical practitioner or dietitian; (b) a medical practice, pharmacy, or responsible institution; or (c) a majority seller of that food for special medical purposes.
Advantages of Agulcator®
Most patients are aware of the long-term health consequences from failure of good glycaemic control and want to improve this. They may also be aware of the limitations of current therapies and have concerns about side effects and cost. Treatment regimens that improve glycaemic control at low cost, with reduction of risk of side effects and prolongation of efficacy, will improve well-being and represent a major breakthrough.
